Clinical Trial Update: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine [Phase 3]

View source ↗

Summary

This clinical trial update reports on a Phase 3 study of galcanezumab (LY2951742) in participants 6 to 17 years old with episodic migraine; the study is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Galcanezumab (galcanezumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Episodic Migraine | Phase 3 | Status: ACTIVE_NOT_RECRUITING